Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (172)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Daratumumab |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Daratumumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Ibrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Ibrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Ruxolitinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Ruxolitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Zanubrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Zanubrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Acalabrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Acalabrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Lenalidomide |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
Lenalidomide
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
Pomalidomide |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
Pomalidomide
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
Venetoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Venetoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Luspatercept |
Erythropoiesis-Stimulating Agent | Hematologic (Anemia) | ||
|
Molecule
Luspatercept
Therapeutic Category
Supportive Care (Growth Factor)
Oncology Type
Hematologic (Anemia)
Drug Class / Mechanism
Erythropoiesis-Stimulating Agent |
||||
Brentuximab Vedotin |
ADC | Hematologic | ||
|
Molecule
Brentuximab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Ciltacabtagene Autoleucel |
Chimeric Antigen Receptor T-Cell Therapy | Hematologic (Leukemia/Lymphoma/Myeloma) | ||
|
Molecule
Ciltacabtagene Autoleucel
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
||||
Polatuzumab Vedotin |
ADC | Hematologic | ||
|
Molecule
Polatuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
DaratumumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
IbrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
RuxolitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
ZanubrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
AcalabrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
LenalidomideImmunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
PomalidomideImmunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
VenetoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
LuspaterceptSupportive Care (Growth Factor) |
|
|
Therapeutic Category
Supportive Care (Growth Factor)
Oncology Type
Hematologic (Anemia)
Drug Class / Mechanism
Erythropoiesis-Stimulating Agent |
|
Brentuximab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Ciltacabtagene AutoleucelCellular Therapy (CAR-T) |
|
|
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
|
Polatuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|